CGRP Forum
Send to a colleague
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

News from the CGRP Forum

Galcanezumab has significant impact on episodic but not chronic cluster headache

A Phase 3 trial of galcanezumab in patients with episodic cluster headache has met its primary endpoint. Galcanezumab significantly reduced weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period (-8.7 for galcanezumab vs -5.2 for placebo, p=0.036).

Read the full report here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Amgen Novartis
© Copyright CGRP Forum 2018. Please click here to unsubscribe from future mailings.